Eisai inks R&D Genomics data deal; cuts 25% US jobs

By Dan Stanton

- Last updated on GMT

Eisai inks R&D Genomics data deal; cuts 25% US jobs

Related tags Pharmacology Drug development Genome

Eisai has inked a deal with a genome analytics firm to aid drug discovery days after announcing it would be cutting 25% of its in-house US workforce.

The collaboration will see Oxford, UK-based Genomics plc partner with Eisai to improve target selection, target validation, indication selection and re-positioning for improving the Japanese pharma’s R&D focus.

“Genomics' research work with Eisai will demonstrate the real value that powerful analyses of large genomic databases can add to drug development pipelines,”​ said Peter Donnelly, who founded Genomics as a spin-out from Oxford University.

The company uses its analytical platform for genomic sequence data analysis and interpretation, which aids pharma firms in improving the drug discovery process. The technology uses algorithms, data-mining, and special software, which – according to the company – can de-risk the drug development process and reduce unnecessary clinical trials by identifying which drugs are likely to be successful.

Financial details of the deal have not been divulged.

R&D cutbacks?

Genomics will be working with Eisai's Integrated Human Genomics (IHGx) Research Unit, a newly formed unit focused on neurodegenerative diseases, auto-immune diseases and cancer immunity.

IHGx Director Nadeem Sarwar said the deal is indication of “Eisai's commitment to leveraging genomic knowledge to accelerate the discovery and development of impactful new medicines.”

The news comes just days after the pharma company announced it was looking to scale back its US operations - including both R&D and manufacturing – and cut a quarter of its workforce in an effort to become more streamlined.

“The actions we are taking will ensure Eisai stays competitive in a rapidly changing business environment,"​ said CEO Yuji Matsue. “Through this realignment, we will be able to redeploy our resources to support the development of our priority late-stage compounds and our current product portfolio."

Related news

Show more

Related products

show more

Related suppliers

Follow us


View more